We are actively recruiting patients to Phase 1/2 clinical trials for LOXO-292 and LOXO-195.
LOXO-292 (RET inhibitor)
LOXO-292 is an oral and selective investigational medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase.
LOXO-292 was designed to inhibit both native RET signaling that drives tumor formation and progression and anticipated acquired resistance mechanisms that could limit the activity and effectiveness of this therapeutic approach.
For more information about the LOXO-292 clinical trial, please refer to www.loxooncologytrials.com. Interested patients and physicians can contact the Loxo Oncology RET Physician and Patient Clinical Trial Hotline for more information about the LOXO-292 clinical trial at 1-855-RET-4-292 or email firstname.lastname@example.org.
LOXO-195 (TRK inhibitor)
LOXO-195 is a selective TRK inhibitor under investigation for addressing and overcoming potential mechanisms of acquired resistance that may emerge in patients receiving VITRAKVI® (larotrectinib) or other multikinase inhibitors with anti-TRK activity.
Acquired resistance to targeted therapies has proven to be an important component of long-term cancer care and targeted therapy drug development. LOXO-195 was developed in anticipation of potential resistance to larotrectinib, and in light of recent published literature regarding emerging mechanisms of resistance to TRK inhibition. LOXO-195 is being investigated as a sequential treatment, to follow larotrectinib or another TRK inhibitor, with the potential to extend the total time of benefit from TRK inhibition.
For additional information about the LOXO-195 clinical trial, please refer to www.loxooncologytrials.com. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or email email@example.com.
LOXO-292 is currently being evaluated in a global, multi-center Phase 1/2 trial in patients with advanced solid tumors.